Heart Transplant Clinical Trial
Official title:
Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-grafting in Adult Heart Transplant Recipients.
The main objective is to develop pharmacokinetic methods for individual dose adjustment of
the global immunosuppressive treatment (cyclosporine, tacrolimus, mycophenolate mofetil and
everolimus, taking into account the pharmacokinetic interactions), in order to optimise the
efficiency and reduce the potentially severe sides effects of these drugs.
Forty five heart-transplant patients are to be included in this phase IV study to obtain a
minimum of 10 patients treated with tacrolimus-mycophenolate, 10 with
cyclosporine-mycophenolate and 20 with everolimus-cyclosporine.
Ten to 11 blood samples will be collected within the 8 to 12 hours post-dose in each patient
and the immunosuppressive drug concentrations will be measured by LC-MS/MS.
The pharmacokinetic models and Bayesian estimators thus developed will provide tools for
individual dose adjustment of immunosuppressive drugs simultaneously, at different
post-transplant periods, using the area under the concentration-time curve (AUC) estimated
using a limited number of time-points (2 or 3).
For each heart transplant patient, 10 to 11 blood samples (5 mL each) will be collected following dosing of he immunosuppressive drugs (at T0, T20', T40', T60', T90', T2h, T3h, T4h, T6h, T8h and T10h + T12h for inpatients), at several post-transplant periods (7 to 15 days, 1 month, 3 month and 1 year after transplantation). One more blood sample will be taken at D7-14 for pharmacogenetic analyses. ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02964026 -
Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients
|
N/A | |
Active, not recruiting |
NCT05096299 -
OCS Heart EXPAND + CAP Continued Follow-Up
|
||
Completed |
NCT02323321 -
International EXPAND Heart Pivotal Trial
|
N/A | |
Not yet recruiting |
NCT05025774 -
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
|
||
Recruiting |
NCT05933083 -
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
|
N/A | |
Completed |
NCT03150095 -
Health Coaching to Improve Self-Management in Thoracic Transplant Candidates
|
N/A | |
Active, not recruiting |
NCT02554578 -
Impact of mHealth in Heart Transplant Management
|
N/A | |
Terminated |
NCT03346278 -
Text Message Intervention to Improve Cardiac Rehab Participation
|
N/A | |
Active, not recruiting |
NCT05741723 -
OCS DCD Heart + CAP Continued Follow-Up
|
||
Completed |
NCT03831048 -
Donors After Circulatory Death Heart Trial
|
N/A | |
Completed |
NCT04615182 -
Donor After Circulatory Death Heart CAP Trial
|
N/A | |
Completed |
NCT02597543 -
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
|
Phase 4 | |
Recruiting |
NCT05824364 -
Exercise aNd hEArt Transplant
|
N/A | |
Enrolling by invitation |
NCT05390411 -
Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial
|
N/A | |
Recruiting |
NCT04770012 -
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
|
Phase 3 | |
Terminated |
NCT01769443 -
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
|
Phase 2 | |
Completed |
NCT00466804 -
Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients
|
N/A | |
Recruiting |
NCT06426173 -
Effect of Resistance Training in Patients on the Waiting List for Heart Transplant
|
N/A | |
Not yet recruiting |
NCT05459181 -
HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
|
N/A | |
Terminated |
NCT01485757 -
Prospective L-arginine Study
|
Phase 1 |